Theravance Biopharma, INC 10-Q quarterly reports

Theravance Biopharma announced a definitive agreement to be acquired by Zymeworks Inc. for $17.00 per share in cash, plus a contingent value right, following a strategic review.

Theravance Biopharma announced first-quarter 2026 financial results, reporting a net loss of $4.9 million, and confirmed the wind-down of its ampreloxetine program following unsuccessful Phase 3 trial results.

Theravance Biopharma reported a significant net income for the nine months ended September 30, 2025, driven by a $75.1 million gain from the sale of its remaining TRELEGY royalties to GSK, while advancing its ampreloxetine Phase 3 study.

Theravance Biopharma reported significant net income and cash flow for Q2 2025, driven by a $225 million sale of TRELEGY royalties to GSK and continued growth in YUPELRI sales.

Theravance Biopharma announces its Q1 2025 financial results, highlighting revenue growth from YUPELRI and advancements in the ampreloxetine clinical program.

Theravance Biopharma's Q3 2024 results show a net loss of $12.7 million, but YUPELRI sales hit a record high, driven by increased demand and market share.

Theravance Biopharma's second quarter 2024 results show stable YUPELRI sales and continued progress in the development of ampreloxetine.

Theravance Biopharma's first quarter 2024 results show a 39% increase in revenue primarily driven by higher YUPELRI sales, while the company continues to advance its ampreloxetine program.